NCT07206056: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Sponsor: Novartis Pharmaceuticals. Phase: PHASE1. Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer